

Date: Monday, October 07, 2024

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400001,
Maharashtra, India

Respected Sir/ Madam,

Open Offer made by M/s Lenus Finvest Private Limited, along with the Individual Promoters, namely being, Mr. Siddhant Laxmikant Kabra, Mr. Laxmikant Ramprasad Kabra, Mr. Bhavesh Dhirajlal Tanna, and M/s Laxmikant Kabra HUF, for acquisition of up to 36,03,716 Offer Shares representing 26.00% of the Expanded Voting Share Capital of Eiko Lifesciences Limited, the Target Company, from the Public Shareholders of the Target Company.

We would like to inform you that, M/s Lenus Finvest Private Limited (Acquirer 1), Mr. Siddhant Laxmikant Kabra (Acquirer 2), Mr. Laxmikant Ramprasad Kabra (Acquirer 3), Mr. Bhavesh Dhirajlal Tanna (Acquirer 4), and M/s Laxmikant Kabra HUF (Acquirer 5), who are the existing promoter of the Eiko Lifesciences Limited ('**Target Company**'), in accordance with the provisions of Regulations 2 (1) (s), and 2 (1) (t) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended ('**SEBI (SAST) Regulations**'), read with Regulations 2 (1) (oo) and 2 (1) (pp) of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and subsequent amendment thereto ('**SEBI (ICDR) Regulations**'), (hereinafter collectively referred to as the '**Acquirers**') intend to acquire up to 36,03,716 Offer Shares representing 26.00% of the Expanded Voting Share Capital of the Target Company

In culmination of the aforesaid facts, we would like to inform you that, in accordance with the provisions of Regulation 12 (1) of the SEBI (SAST) Regulations, we Swaraj Shares and Securities Private Limited, have been appointed as the Manager to the Offer ('**Manager**'), and the Acquirers have announced an open offer in compliance with the provisions of Regulations 3(1) and such other applicable regulations of the SEBI (SAST) Regulations for acquisition of up to 36,03,716 Offer Shares representing 26.00% of the Expanded Voting Share Capital of the Target Company from the Public Shareholders of the Target Company at an Offer Price of ₹53.10/- per Offer Share, determined in accordance with the parameters prescribed under Regulation 8 of the SEBI (SAST) Regulations.

In light of the above and in accordance with the provisions of Regulations 26(7) of the SEBI (SAST) Regulations, the Committee of the Independent Directors of the Target Company have hereby published their recommendations of the for the aforesaid Offer today, i.e., Monday, October 07, 2024 in Financial Express (English daily) (All Editions), Jansatta (Hindi daily) (All Editions), and Mumbai Lakshadeep (Marathi Daily) (Mumbai Edition), ('**Newspapers**') and the same has been enclosed herewith for your kind perusal ('**Recommendations of the IDC**').

We hope your good self will find the above in order and we request you to kindly upload the Recommendations of the IDC on your website at the earliest.

Thanking you,

Yours faithfully
For Swaraj Shares and Securities Private Limited


Mr. Tanmoy Banerjee
Director
Encl.: As above

Swaraj Shares and Securities Private Limited

 tanmoy@swarajshares.com  pankita@swarajshares.com  www.swarajshares.com
 +91 9874283532  +91 8097367132

Registered Office - 21 Hemant Basu Sarani, 5th Floor, Room No 507, Kolkata - 700001, West Bengal, India

Branch Office - Unit 304, A Wing, 215 Atrium, Near Courtyard Marriot, Andheri Kurla Road, Andheri East, Mumbai - 400093,
Maharashtra, India

EIKO LIFESCIENCES LIMITED		
Corporate Identification Number: L65930MH1977PLC258134;		
Registered Office: 604, Centrum, Opp. TMC Office, Near Salkar Grande Hotel, Wagle Estate Thane - 400604, Maharashtra, India;		
Tel: 022-25390009/ 022-25439095 /+91-9820171270; Website: www.eikolifesciences.com;		
Email ID: investor.relations@eikolifesciences.com		
Recommendations of the Committee of Independent Directors ('IDC') of Eiko Lifesciences Limited ('Target Company') in relation to the Open Offer ('Offer') made by M/s. Lenus Finvest Private Limited (Acquirer 1), Mr. Siddhant Laxmikant Kabra (Acquirer 2), Mr. Laxmikant Ramprasad Kabra (Acquirer 3), Mr. Bhavesh Dhirajlal Tanna (Acquirer 4), M/s. Laxmikant Ramprasad Kabra HUF (Acquirer 5), (hereinafter collectively referred to as 'Acquirers'), to the Public Shareholders of the Target Company under the provisions of Regulation 26(7) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and Subsequent Amendments thereto ('SEBI (SAST) Regulations').		
Date	Friday, October 04, 2024	
Name of the Target Company	Eiko Lifesciences Limited	
Details of the Offer pertaining to the Target Company	Open offer being made by the Acquirers for acquisition of up to 36,03,716 Offer Shares, representing 26.00% of the Expanded Voting Share Capital of the Target Company, at a price of ₹33.10/- per Offer Share, payable in cash, assuming full acceptance aggregating to a maximum consideration of ₹19,13,57,319.60/- payable in cash.	
Names of the Acquirers and Persons Acting in Concert with the Acquirers	M/s. Lenus Finvest Private Limited, Mr. Siddhant Laxmikant Kabra, Mr. Laxmikant Ramprasad Kabra, Mr. Bhavesh Dhirajlal Tanna, M/s. Laxmikant Ramprasad Kabra HUF. There is no person acting in concert for this Offer.	
Name of the Manager to the Offer	Swaraj Shares and Securities Private Limited	
Members of the Committee of Independent Directors (IDC)	Sr. No.	Name of the Independent Directors
	1.	Mr. Rajkumar Govindas Baheti Chairperson
	2.	Mrs. Hasli Arjav Doshi Member
	3.	Ms. Kajal Dhanpatraj Kothari Member
IDC Member's relationship with the Target Company (Director, Equity shares owned, any other contract/relationship), if any	1. All IDC Members are Independent Directors and Non-Executive Directors on the Board of the Target Company. 2. IDC Members have not entered into any other contract or have other relationships with the Target Company.	
Trading in the Equity Shares/other securities of the Target Company by IDC Members	IDC Members have confirmed that they have not traded in the Equity Shares of the Target Company from the date of the Public Announcement till the date of this Recommendations.	
IDC Member's relationship with the Acquirer (Director, Equity shares owned, any other contract/relationship), if any.	None of the IDC Members hold any contract, nor have any direct or indirect relationship with the Acquirer, their promoter, directors, and shareholders, in their personal capacities.	
Trading in the equity shares/other securities of the acquirer by IDC Members	IDC Members have confirmed that they have not traded in the equity shares of the Corporate Acquirer.	
Recommendation on the Open offer, as to whether the offer, is or is not, fair, and reasonable	Based on the review of the Offer Documents issued by the Manager to the Offer on behalf of the Acquirers, IDC Members believe that the Offer is fair and reasonable and in line with the SEBI (SAST) Regulations. The shareholders may independently evaluate the Offer, the market performance of the Equity Shares, and take an informed decision in the best of their interests. Further, the Public Shareholders, should independently review the Letter of Offer dated Monday, September 30, 2024, including the risk factors described therein before taking any decision in relation to this Offer.	
Summary of reasons for the recommendation	IDC Members have taken into consideration and reviewed the following Offer Documents for making the recommendation: a) The Public Announcement dated Wednesday, July 10, 2024 ('Public Announcement'); b) Detailed Public Statement dated Monday, July 15, 2024, in connection with this Offer, published on behalf of the Acquirers on Tuesday, July 16, 2024, in Financial Express (English daily) (All India Edition), Jansatta (Hindi daily) (All India Edition) and Mumbai Lakshadweep (Marathi daily) (Mumbai Edition) ('Detailed Public Statement'); c) Draft Letter of Offer dated Wednesday, July 24, 2024, filed and submitted with SEBI pursuant to the provisions of Regulation 16 (1) of the SEBI (SAST) Regulations ('Draft Letter of Offer'); d) The Letter of Offer along with Form of Acceptance and Form SH-4 dated Friday, September 27, 2024 ('Letter of Offer'). The Offer Price is in terms of Regulation 8(2) of the SEBI (SAST) Regulations. Based on the review of the aforesaid Offer Documents, the IDC Members are of the view that the Offer Price is in line with the parameters prescribed by SEBI in the SEBI (SAST) Regulations.	
Disclosure of Voting Pattern	These recommendations have been unanimously approved by the IDC Members	
Details of Independent Advisors, if any	None	
Any other matter to be highlighted	None	
<p><i>Terms not defined herein carry the meaning ascribed to them in the Letter of Offer dated Friday, September 27, 2024.</i></p> <p>To the best of our knowledge and belief, after making the proper enquiry, the information contained in or accompanying this statement is, in all material respect, true and correct and not misleading, whether by omission of any information or otherwise, and includes all the information required to be disclosed by the Target Company under the Regulations.</p> <p style="text-align: right;">For and on behalf of the Committee of Independent Directors Eiko Lifesciences Limited sd/- Mr. Rajkumar Govindas Baheti Chairman & Director of the IDC (DIN: 05164182)</p>		
Place: Mumbai		
Date: Friday, October 04, 2024		